WP
PMVP icon

Woodline Partners’s PMV Pharmaceuticals PMVP Stock Holding History

Woodline Partners’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,791,553
Closed -$5.55M – 614
2023
Q4 		$5.55M Buy
1,791,553
+700,813
+64% +$1.85M 0.06% 306
2023
Q3 		$6.7M Buy
1,090,740
+357,005
+49% +$2.45M 0.08% 273
2023
Q2 		$4.59M Buy
733,735
+557,847
+317% +$2.92M 0.05% 304
2023
Q1 		$839K Sell
175,888
-832,799
-83% -$5.86M 0.01% 487
2022
Q4 		$8.78M Buy
1,008,687
+109,380
+12% +$1.17M 0.12% 235
2022
Q3 		$10.7M Buy
899,307
+429,424
+91% +$6.2M 0.15% 194
2022
Q2 		$6.7M Sell
469,883
-248,210
-35% -$3.61M 0.1% 219
2022
Q1 		$15M Buy
718,093
+419,483
+140% +$7.4M 0.24% 125
2021
Q4 		$6.9M Sell
298,610
-108,755
-27% -$2.63M 0.1% 247
2021
Q3 		$12.1M Buy
407,365
+168,284
+70% +$5.37M 0.2% 142
2021
Q2 		$8.17M Buy
239,081
+15,391
+7% +$514K 0.15% 158
2021
Q1 		$7.36M Sell
223,690
-1,131
-0.5% -$44.6K 0.16% 158
2020
Q4 		$13.8M Buy
224,821
+17,400
+8% +$683K 0.37% 85
2020
Q3 		$7.36M Buy
+207,421
New +$7.63M 0.24% 105

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Woodline Partners's PMVP Position: Q1 2024 in Review

Woodline Partners sold out of PMV Pharmaceuticals (PMVP) in Q1 2024, closing a stake of 1,791,553 shares — an estimated $5.55M sold.

Woodline Partners first reported a position in PMVP in Q3 2020 and held it in 14 quarters. The position peaked at $15M in Q1 2022. 99 funds tracked by Wall St. Rank hold PMVP as of Q1 2024.

  • Woodline Partners reported no remaining PMV Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Woodline Partners sold 1,791,553 PMV Pharmaceuticals shares in Q1 2024, an estimated $5.55M.
  • Woodline Partners first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 14 quarters.
  • Woodline Partners's PMV Pharmaceuticals position peaked at $15M in Q1 2022.
  • 99 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q1 2024.

Based on Woodline Partners's 13F filing for Q1 2024, filed 15 May 2024.